Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Abstract Background Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and Drug Administration for locally advanced or metastatic urothelial cance...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Fatima Karzai, David VanderWeele, Ravi A. Madan, Helen Owens, Lisa M. Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L. Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B. Trepel, Maria J. Merino, Ryan Dittamore, Jennifer Marté, Renee N. Donahue, Jeffrey Schlom, Keith J. Killian, Paul S. Meltzer, Seth M. Steinberg, James L. Gulley, Jung-Min Lee, William L. Dahut
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMJ Publishing Group 2018-12-01
Edice:	Journal for ImmunoTherapy of Cancer
Témata:	Durvalumab Olaparib mCRPC Abiraterone Enzalutamide Immunotherapy
On-line přístup:	http://link.springer.com/article/10.1186/s40425-018-0463-2
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!